Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

May 4, 2023

NASDAQ US Health Care Biotechnology earnings 43 min

Earnings Call Speaker Segments

Cecilia Jones

executive
#1

Thanks, Vera. Hello, everyone, and good morning. We're glad to have you on Agios's first quarter 2023 conference call. Slides for today's call are available in the investor section of our website, agios.com. Joining me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; and Tsveta Milanova, our Chief Commercial Officer. Before we begin, please be aware that certain statements made on this call will contain forward-looking statements. Due to various risks, uncertainties and other factors — including those described in our most recent filings with the SEC and any other future filings we may make with the SEC — actual events and results could differ materially from those expressed or implied by any forward-looking statements. With that, I'll hand the call over to Brian.

Brian Goff

executive
#2

Thanks, Cecilia. Morning, everybody, and I appreciate you all being here. Agios leads the field as a pioneer in PK activation, committed to creating and bringing to patients transformative treatments for those facing rare diseases. Across several disease areas, we keep producing steady, persuasive results with our PK activators, which shows what this distinctive mechanism of action could do to change patient function, quality of life, and long-term outcomes in PK deficiency, thalassemia, sickle cell disease, and lower risk MDS. Owing to the excitement among our clinical investigators and the operational strength of our R&D group, I'm happy to share that screening has now been closed in our phase III thalassemia studies, which collectively cover the full thalassemia population, and we expect to finish enrolling these studies later this month. On behalf of everyone at Agios, I want to thank the patients, caregivers, and physicians for staying involved in these trials. As Sarah will explain in greater depth, how quickly these studies enrolled underscores the considerable unmet need in these areas and strengthens our confidence in the wider clinical development strategy we're pursuing. Along these lines, we keep moving our strong clinical stage pipeline forward and remain on schedule to report the data readout from the phase II portion of the operationally seamless phase II, III RISE UP study of PYRUKYND in sickle cell disease, along with the go, no-go decision to phase III, in the middle of this year. Reflecting how well investigators at our clinical trial sites have received both PYRUKYND and AG-946, we keep getting favorable feedback from patients and clinicians alike regarding the difference PYRUKYND is making for people living with PK deficiency in the real world; it's encouraging that the efficacy of PYRUKYND seen in the clinical trial experience is carrying over into persistency on therapy in the real world, and we think this bodes well for the possible long-term impact of PK activation on how patients feel and function not only in PK deficiency, but in thalassemia, sickle cell disease, and lower risk MDS too. Tsveta will give a thorough update on our commercial performance in just a few minutes. As you'll hear from Cecilia, we closed the first quarter of 2023 with an enviable cash position, holding roughly $1 billion on the balance sheet. As a reminder, when we divested our oncology business to Servier in April of 2021, we kept rights to a potential milestone tied to FDA approval of vorasidenib plus royalties on potential US net sales. So we were glad to learn that Servier's phase III trial of vorasidenib in patients with residual or recurrent IDH-mutant low-grade glioma hit both its primary endpoint and key secondary endpoints; this data highlights Agios' strong record in discovering and developing therapeutics for disease areas with high unmet need, which so far covers five approved indications across three separate products. Beyond the imminent phase II data readout for PYRUKYND in sickle cell disease, several other milestones should be reached before this year ends. These include finishing enrollment for the phase III trials of PYRUKYND in thalassemia, getting more than 50% of patients signed up in the phase III ACTIVATE-Kids and ACTIVATE-KidsT studies of PYRUKYND for pediatric PK deficiency, wrapping up enrollment for the phase II-A trial of AG-946 in lower risk MDS, and submitting the IND for our PAH stabilizer aimed at treating PKU. Last, as we look ahead to what should be a catalyst-rich stretch over the coming years, we expect readouts from the phase III trials of PYRUKYND in thalassemia during 2024, plus readouts from the phase III trials of PYRUKYND in sickle cell disease and pediatric PK deficiency during 2025; with that, I'll hand the call over to Sarah. Sarah?

Sarah Gheuens

executive
#3

Thank you, Brian. During the year's opening quarter, everyone on our team achieved enormous strides in carrying out our pipeline of PK activators, which leads the industry; we were delighted to accept the 2023 Citeline Award for Excellence in Rare Disease Drug Development. That honor acknowledges the approval of PYRUKYND for PK deficiency along with the meaningful potential it holds for other hemolytic anemias, among them sickle cell disease and thalassemia. I'll now give a short update on every one of our programs, starting with thalassemia, a setting where PYRUKYND could become the initial oral treatment capable of improving hemolytic anemia and ineffective erythropoiesis across every thalassemia subtype. To be specific, the phase III thalassemia program is made up of two randomized placebo-controlled trials, and each one is enrolling patients who have both alpha-thalassemia and beta thalassemia. ENERGIZE is enrolling patients who are not regularly transfused, and its primary endpoint is hemoglobin response. ENERGIZE-T is enrolling patients who are regularly transfused, and its primary endpoint is transfusion reduction response. Because of our operational excellence in clinical development and the enthusiasm our investigators have shown for what PYRUKYND might do in this indication, screening has closed in both ENERGIZE and ENERGIZE-T, and we anticipate finishing enrollment later this month, with top-line data reported next year. Moving to sickle cell disease, our aim is to tackle the substantial unmet patient need through an oral therapy that betters anemia, cuts sickle cell pain crises, and delivers a durable improvement in how patients feel and function. To achieve this differentiated target product profile, we are moving forward with the operationally seamless phase II, III RISE UP study of PYRUKYND in adults who have sickle cell disease. Hemoglobin response and safety serve as the primary endpoint of the fully enrolled phase II portion of the RISE UP study, and we remain on track to disclose the phase II data readout and the go/no-go decision regarding phase III in the middle of this year. That decision will be driven by data and guided by the protocol-defined go/no-go criteria in the phase II portion of RISE UP, which includes any additional data from the phase II secondary endpoint and longer-term data from the ongoing extension studies of the investigator-sponsored trials at the NIH and Utrecht University. Lastly, we keep advancing the phase III ACTIVATE-Kids and ACTIVATE-KidsT studies of PYRUKYND in pediatric PK deficiency, since we aim to deliver the first approved therapy for children living with this disease; our expectation is to enroll at least half of the patients in each of these studies by the end of the year. Now turning to the development of AG-946, our novel PK activator that could strengthen our PK activator franchise and make once-a-day dosing possible. As a reminder, lower risk MDS represents roughly 70% of MDS cases and shares an underlying pathophysiology with other disease areas in our pipeline. Given the data we have generated in the phase I study of AG-946 in healthy adults, we look forward to progressing this study and expect to complete enrollment of the phase II-A portion by the end of this year. While we keep pushing forward with the work on our PK activators, our goal is also to broaden what we're building beyond PK activation, doing so through business development as well as by moving our earlier-stage pipeline ahead. Along those lines, we're continuing to make headway with our small molecule program, the phenylalanine hydroxylase, or PAH, stabilizer, which is meant to tackle the root cause of phenylketonuria directly. For this program, we're aiming to file an IND before this year is over. Taking a step back, I feel a great deal of enthusiasm about how much the team accomplished in carrying out work across our portfolio during this quarter, and I'm eager for the many significant milestones coming in the months ahead. Having said that, I'll hand things over now to Tsveta.

Tsveta Milanova

executive
#4

Thank you, Sarah. Everyone in our commercial team is intensely committed to carrying out a thorough plan that touches every stage of the patient journey — starting with disease awareness and continuing through reimbursement, adherence, and persistency. Through those efforts, we intend to make the most of the opportunity presented by the ongoing launch in PK deficiency, while also developing the capabilities required to capture the full potential of upcoming launches we anticipate in thalassemia, sickle cell disease, and lower risk MDS. Having a clear benefit/risk profile is one of the essential building blocks behind any launch that succeeds. In line with the favorable responses we heard from patients and providers, we are delighted that the persuasive results seen with PYRUKYND in the PK deficiency clinical trial program have kept translating into sustained treatment use in the real world. More specifically, data from our market research show that close to 100% of the targeted healthcare providers we surveyed would probably recommend PYRUKYND for their adult patients living with PK deficiency. From the perspective of clinicians, the main reasons behind those recommendations involve better hemoglobin levels, fewer transfusions, and effects on long-term disease complications and comorbidities. Although our attention remains on finding patients and raising disease awareness, since launch, discontinuations have stayed low on the whole. Reauthorizations have not stood in the way, and treatment persistency has stayed robust past six months from the time treatment begins. Taken together, we see this as a reflection of both the favorable effect PYRUKYND has on how patients feel and function and the strength of our commercial capabilities, which include market access and patient services. During the first quarter of 2023, which was the fourth full quarter of launch, we brought in $5.6 million in net PYRUKYND revenue. Altogether, 127 patients have completed a prescription enrollment form, or PEF, so far, among them 22 during the fourth quarter of 2023. That marks a 21% increase compared with the fourth quarter of 2022; it has resulted in a net 89 patients on therapy, which is a 14% rise from the prior quarter. The patients on therapy keep coming from an expanding and varied provider base made up of 113 physicians, and they reflect a wide demographic and disease manifestation range that aligns with the adult PK deficiency population. I have full confidence that reinforcing the commercial capabilities we are prioritizing right now — such as our capacity to spot providers likely to treat patients suitable for PYRUKYND, boost diagnostic efficiency, engage a wide array of prescribers, and sustain long-term adherence and reimbursement — will help us maximize the current launch's potential and establish the groundwork for possible launches in considerably larger patient populations. The next launch we may pursue is in thalassemia, where roughly 60% of patients lack an approved therapy in the U.S. What matters greatly is that PYRUKYND could become the first oral therapy capable of improving hemolytic anemia and ineffective erythropoiesis across the entire spectrum of thalassemia patients, covering both alpha-thalassemia and beta thalassemia. At present, alpha-thalassemia has no approved treatment options, so it will call for a specific emphasis on patient identification and disease education, drawing on the capabilities we are building through the current launch in PK deficiency. Beta thalassemia, in contrast, represents the disease's more prevalent type, accounting for roughly two-thirds of thalassemia diagnoses within the U.S. Because it affects more people and the field is more crowded, our view is that gaining traction in beta thalassemia will demand heavier focus on market access plus PYRUKYND's full product profile, spanning efficacy, safety, and how it is administered. Considered together, every one of these prospective launches calls for a commercial approach tailored to it, and our goal is to draw on strengths built during our existing launch so we can serve the requirements of all these patient groups. Across the U.S. and EU Five, the thalassemia patient population in its entirety spans roughly 18,000 to 23,000 individuals, along with a substantial addressable market beyond those regions, for example the Gulf Cooperation Council countries, or GCC, where thalassemia prevalence runs eight to 9 x greater than in the U.S; we anticipate growing our commercial abilities to match the distinct requirements of the diseases we target and to bring transformative new treatment choices to these places of deep unmet patient need. Having said that, I'll hand the call over now to Cecilia.

Cecilia Jones

executive
#5

Thank you, Tsveta. You can find our financial results for the first quarter of 2023 in the press release that came out this morning, and I'll walk through the highlights. Additional specifics will appear in our 10-Q, which we expect to file later on today. Net revenue for PYRUKYND during the first quarter of 2023 reached $5.6 million, which represents a $1.3 million gain over Q4 2022. Since PYRUKYND is the initial treatment approved for this ultra-rare patient population, we're still collecting data and insights regarding how the launch is progressing, and we won't be offering guidance right now. In line with what we see with other rare disease launches, gross to net remains within the 10%-20% range. Cost of sales came to $0.6 million for the quarter. Now let's look at expenses on the balance sheet. R&D expenses totaled $67.3 million in the first quarter, which is $2.8 million lower than the first quarter of 2022. That reduction was mainly attributable to the $1.5 million in reimbursable transition-related expenses we gave to Servier during the first quarter of 2022 in connection with the sale of the oncology business. SG&A expenses came in at $28.4 million for the first quarter, down $3.1 million from the first quarter of 2022, largely because of a decrease in workforce-related expenses. Just to remind everyone, the TIBSOVO royalty — which appeared under royalty income from gain on sale of oncology business on our income statement — is no longer applicable, since we sold our right to 5% royalties on U.S. net sales of TIBSOVO to Sagard for a one-time payment of $131.8 million in October 2022. Through the divestiture of our oncology business to Servier, we kept rights to a potential $200 million milestone contingent on FDA approval of vorasidenib, plus 15% royalties on potential U.S. net sales. We closed out the quarter with cash equivalents and marketable securities of roughly $1 billion; we anticipate that our cash equivalents and marketable securities, along with expected product revenue and interest income, will allow us to carry out our operating plan — this includes funding the currently planned development programs for mitapivat, AG-946, and our PAH stabilizer, as well as commercializing mitapivat outside the U.S. via one or more partnerships. To preserve our strong cash position, we'll stay focused on proactively managing our cost base and taking a disciplined approach to cash allocation. At this point I'll hand the call back to Brian for his closing remarks.

Brian Goff

executive
#6

Appreciate that, Cecilia. Because enrollment has moved quickly in our active trials for PYRUKYND and thalassemia, because real-world PYRUKYND treatment has kept going strong in our present launch for PK deficiency, and because our balance sheet remains solid, our team feels motivated and is concentrating on pushing forward our industry-leading pipeline of PK activators to tackle the serious unmet needs of patients who struggle with rare hematologic diseases. Looking toward the clinical and regulatory milestones we anticipate during the remainder of the year, we'll keep working to act as careful stewards of our balance sheet and to assess worthwhile chances for creating value. Last, I want to express gratitude to every one of our employees for their effort and commitment to our mission of changing the lives of patients who live with rare diseases, as well as to all of our partners, among them the physicians, patients, caregivers, and participants in our clinical development programs. With that said, we'll now open the call for questions.

Gregory Renza

analyst
#7

Excellent, and thanks, Brian, along with the whole team. Nice work on the momentum. I appreciate you fielding this. Brian, if I can, maybe stick with the shorter horizon for a moment. I realize there's only so much you and everyone else can share regarding the upcoming sickle cell readout. But could you remind us, or maybe give us a sense of the different scenarios you're weighing as you think about your no-go call? What's baked into that thinking when you consider how the data might land and what the fresh information coming your way could look like? And on your end too, Brian, the steadiness of the data — you've said you've been quite happy with it as time has gone on, so how does that play into the result as well? Thanks a lot.

Brian Goff

executive
#8

Absolutely. Morning, Greg, and I appreciate the question. When it comes to sickle cell disease, let me start by praising Sarah and her group once more for how well they've advanced things, not only in sickle cell and bringing us to a data readout at the year's midpoint. As we said on the call, I'm particularly proud that thalassemia, now that screening is done, has us set up for a readout in that area during 2024, which matters just as much. On sickle cell, naturally we've got multiple scenarios we're preparing for. We're aiming for and anticipating a win, naturally, and that's the reason the trial was built to run seamlessly from phase II into III. If phase II reads out positively, the wonderful part is that Sarah and the team could move fast and build on the very same clinical site infrastructure we've established in phase II. Clearly this is an area of tremendous unmet patient need, and in that case we're anxious to push ahead on their behalf. As for precisely what we want to see in the data, and we've discussed this often, we'll take a holistic view when reviewing it. The primary endpoint in the phase II RISE UP readout, naturally, will center on hemoglobin improvement; we've got secondary endpoints, markers of hemolysis and similar things. Naturally, safety is going to be a crucial piece, and it will steer us toward the dose we'd take forward if things go well. Broadly speaking, our thinking on sickle cell disease is that we'll be seeking a hemoglobin plus dynamic. That might involve hemoglobin along with a VOC pattern, even though this is a study of 12 weeks and wasn’t built specifically to assess VOCs; it might also be about how patients feel and function; we understand, after examining the sickle cell disease space for a long period, that this is an extremely important factor; what matters isn’t only short-term patient success, but whether someone can remain on a treatment over the long term, which, incidentally, explains why the persistency we’ve observed thus far in our PKD launch encourages us so much. Perhaps I’ll pause here and simply check, Sarah, whether you want to add something regarding the scenarios.

Sarah Gheuens

executive
#9

Actually, I believe that topic has been addressed. The design of the study strikes us as quite promising, since it permits us to adapt to the various situations we may encounter.

Brian Goff

executive
#10

Once more, Greg, I want to emphasize that we are, as you know, enthusiastic about what lies ahead. A sickle cell disease readout is scheduled for us at the midway point of this year. Then there's thalassemia, for which we will be examining the readout during 2024. There's also AG-946, for which we are seeking proof of concept at year-end in our phase II-A trial involving low-intermediate risk MDS. Further back in our research pipeline, there is the PAH stabilizer that we are advancing toward an IND by year-end; the upcoming stretch is quite full, but I appreciate the question once more.

Gregory Renza

analyst
#11

Thanks, Brian.

Brian Goff

executive
#12

You bet.

Tess Romero

analyst
#13

Morning, everyone. I really appreciate you taking my question. You've described several elements that would play into whether mitapivat moves ahead or not in sickle cell disease. Could you remind us where things stand with the phase I sickle cell disease cohort for AG-946? Do any findings from patients receiving AG-946 play a role in that choice? Put another way, is there a situation where you might decide to advance AG-946 rather than mitapivat? Many thanks.

Brian Goff

executive
#14

Thanks very much, Tess. I'll ask Sarah to address that.

Sarah Gheuens

executive
#15

Hello, Tess. Regarding AG-946, the phase I trial is still in progress, and we haven't shared which time points we'll use for presenting data. As for the second half of your question, AG-946 and mitapivat sit at completely different stages of development. You know, AG-348 has established — so mitapivat has established, you know, a substantial safety profile, has far longer exposure, and is really, you know, beyond phase I development. Swapping one compound for the other isn't something we see as feasible simply because each product must accumulate its own safety profile. From our perspective, AG-946 is less advanced right now.

Brian Goff

executive
#16

Tess, I want to emphasize this point once more, and it's how I opened the call: since Agios leads the field in PKR activators, we're glad to be advancing not just one but a pair of them through clinical trials. As you pointed out, that hands us a substantial amount of optionality. The readout we're looking forward to in the near term would come from the low intermediate risk MDS patient population, again around the end of the year. Being able to stratify across separate therapeutic areas using a pair of PKR activators is a real edge once we reach that data readout — and if it's positive, as we gear up for launch and consider the economics around it, holding two is notably better than having every therapy concentrated in a single one. Thanks once more for the question.

Tess Romero

analyst
#17

Thank you.

Mark Breidenbach

analyst
#18

Hey, good morning, everyone. Appreciate you taking our questions. I've got two quick ones. First, regarding the ENERGIZE and ENERGIZE-T trials, which are almost done with enrollment, I'm wondering whether you've noticed any patterns in particular regions where patients are being enrolled most quickly, since these studies have such a large number of clinical sites outside the US, and could that pattern end up shaping your regulatory filing strategy, meaning which territories you'd file in first? My second question concerns vorasidenib and possibly Servier's plans for a future NDA filing. Do you have any clarity on when such a filing might happen? Thanks for taking the questions.

Brian Goff

executive
#19

Sure. Thanks a lot, Mark. We'll take those in sequence. Sarah, you wanna start off with ENERGIZE-T and the clinical trial geographies?

Sarah Gheuens

executive
#20

Absolutely. In the past, we've shared how our clinical trials are spread around the world. The reason for that is to mirror where thalassemia occurs, and also to mirror how thalassemia breaks down across genotypes, since this program was built to bring a product to every thalassemia patient — that means alpha as well as beta thalassemia, both regularly and non-regularly transfused. That's how the clinical development program was structured, and it's also structured so that enrolling these trials that way is workable. Up to now, the way that has turned out has pleased us a great deal. The patients we enroll in our clinical trials truly mirror how thalassemia is distributed globally, so as of today we see no need to alter any part of our regulatory strategy.

Brian Goff

executive
#21

Before we move on to Cecilia for the question about vorasidenib, I want to mention that having Tsveta Milanova with us as our Chief Commercial Officer is a real benefit, Mark, especially when we consider, as you raised in your question about launch sequencing, what successful data could mean. As Sveta discussed during her remarks, thalassemia represents an addressable market that is uniquely concentrated from a geographic standpoint. We intend to be especially deliberate regarding the sequencing, partly, naturally, to reach as many patients as possible in those geographies, but also keeping in mind economics that maximize value when it comes to pricing and similar matters. Once again, all of this obviously depends on positive data, yet it places us in a strong position given how concentrated that population is. Having Tsveta with us as a world-class authority on bringing rare disease products to a global scale is a genuine advantage. Perhaps we can have Cecilia offer her thoughts on vorasidenib.

Cecilia Jones

executive
#22

Absolutely. We're clearly thrilled to learn about the phase III data. This is significant for patients facing a substantial unmet need. On our end, we keep the rights to a $200 million milestone tied to FDA approval, along with the $15 million — pardon me, 15% royalty on net U.S. sales. As for timing, we don't have clarity at this point; once we do, we'll share an update.

Brian Goff

executive
#23

Clearly, this is happening within Servier's operation, yet the foundational research and advances originated at Agios, so I'm aware many people from Agios are on this call too. I simply want to express that our pride couldn't be greater regarding what this might signify for glioma patients, a group that has seen no advancement over more than 2 decades; this represents yet another achievement in the record Agios has built on numerous fronts, and at present we are applying all of that excellent science toward our work in PKR activation.

Mark Breidenbach

analyst
#24

Thanks so much.

Brian Goff

executive
#25

You bet.

Greg Harrison

analyst
#26

Hi there, and good morning. I appreciate you taking my question. In what ways would you describe your PAH stabilizer as distinct from a medication such as Kuvan? Given that enzyme replacement and gene therapy are either approved or in development, where do you envision it fitting within the PKU treatment landscape?

Brian Goff

executive
#27

Greg, to begin with, good morning. I'll say right away that it's too soon to provide too much on that topic. We're eager to move our PAH stabilizer forward to IND, though I'll hand it over to Sarah for more.

Sarah Gheuens

executive
#28

Our program, similar to every initiative we run, is built around addressing unmet needs within patient communities. Specifically for this particular one, the design will aim for a product profile that we think can deliver a meaningful difference for those living with PKU. Every currently available therapy comes with its own drawbacks. That's exactly what we intend to tackle with this product, establishing differentiation there — whether through the safety profile, or through how much product patients must take, in order to achieve some meaningful difference and genuinely also aim for additional reduction, basically a better improvement of phenylketonuria overall. There will be more updates on this as we advance the molecule. Naturally, things are early at this point, and like any phase, transitioning to IND and afterward phase I, we'll be learning throughout the program's development.

Brian Goff

executive
#29

This is one more strong illustration of the reason we care so deeply about rare diseases. Each therapeutic area we take on is crying out for new thinking and real change. You know, whether we're talking about PKD or sickle cells, which we've already discussed, or thalassemia, MDS, and PAH, that shared trait is what defines where we aim our efforts.

Greg Harrison

analyst
#30

Understood. That clears things up.

Brian Goff

executive
#31

If I might slip in just one brief question about— Brian Goff: Of course.

Greg Harrison

analyst
#32

About the sickle cell program — which forum are you going to use for that data announcement? A press release, or a conference? And will the go/no-go call be shared at the same time, or might it slip later?

Sarah Gheuens

executive
#33

As for the how and the when of announcing, that hinges on when the data reach us, though our plan is a press release. That release won't carry the full data set, since naturally we want to present at a medical meeting. Those two things always require a balancing act. Following the usual Agios approach — I believe this is what we did for earlier programs such as PKD — you should expect something along those same lines.

Brian Goff

executive
#34

Right. What we're aiming for is to provide those with a stake in the company sufficient transparency regarding the reasoning that drives whatever choice we make, in either direction, as informed by the data.

Greg Harrison

analyst
#35

Got it. Thanks again.

Brian Goff

executive
#36

You bet, Greg. Thanks.

Divya Rao

analyst
#37

Hello, everyone. We appreciate you fielding our questions; Divya here, sitting in for Mark. With what's been said about the need to observe this hemoglobin plus response, in the event that the VOC pattern doesn't match the outlook or isn't observed, does the perspective hold that the PRO analysis would be predictive of eventually demonstrating a VOC benefit, or would you say the PROs on their own lend support to this hemoglobin plus commercial profile? To be specific, I suppose, are there certain PROs that carry particular weight?

Sarah Gheuens

executive
#38

We're talking about the phase II readout, correct? The PRO analysis and VOC benefit, everything there will truly arrive at the conclusion of phase III, consistent with our product profile. What we're currently engaged in with the phase II, it has primary endpoints of hemoglobin response and safety, and then certainly secondary endpoints that encompass, you know, PROs, VOCs, hemolytic parameters; those are what we'll be seeking trends in within those datasets; we will obviously be examining the full body of data produced so far across the various studies employing mitapivat in sickle cell disease, and that is being factored in.

Divya Rao

analyst
#39

That's useful. Let me slip in one more as well. Regarding PKD, I suppose first, did we observe any stocking impact during Q1? Since we're now in the second month of reauthorizations, are you noticing any patterns or, I guess, shifts in how payers assess what counts as a response or benefit?

Brian Goff

executive
#40

Thank you, Divya. I'll have Cecilia address the stocking question. Sveta is always keen to discuss launch dynamics. Cecilia.

Cecilia Jones

executive
#41

Appreciate that, Brad. Just to note, our distribution setup is fairly narrow — a single specialty pharmacy plus a single specialty distributor. The stock we keep available isn't large. So quarter-over-quarter, you could notice some swings. These are still modest figures we're dealing with.

Brian Goff

executive
#42

Not much to add there. Right. Tsveta?

Tsveta Milanova

executive
#43

For sure. Like I mentioned during my prepared comments too, the response we've gotten to PYRUKYND's profile has really been encouraging — from patients, from physicians, and on the payer side as well. That applies to treatment initiations, and we're also seeing it with reauthorizations. Up to this point, reauthorizations haven't posed an obstacle. To evaluate reauthorizations, patients draw on the inclusion/exclusion criteria along with the primary endpoint that was defined in the clinical trial. That said, the full picture of the product profile gets weighed, and we observe that in how well reauthorizations go and in the strong persistency we're seeing — although it's still early in the launch with small patient numbers — so patients keep going beyond six months of reauthorization too.

Brian Goff

executive
#44

Hopefully, during what we cover today, it becomes clear that PYRUKYND is working for people with PKD, and we've definitely heard that kind of feedback from patients directly. We're beginning to observe that in the persistency data as well. As Sveta mentioned earlier, our market research has shown that the clinicians on the target list we've built — which includes those who have written prescriptions for PYRUKYND — feel that same excitement. What's shaping this launch isn't really about whether people can get the product or whether they're enthusiastic about it. The real drivers are education, making the diagnostic process more efficient, and getting patients motivated, particularly to start on therapy. That's genuinely where Sveta's commercial attention is pointed.

Tsveta Milanova

executive
#45

That's helpful. Thank you.

Brian Goff

executive
#46

You're welcome.

Anu Midha

analyst
#47

Morning, everyone. Anu Midha here, speaking on behalf of Salveen. I have a single question about the PKD launch. Would you be able to give us an update regarding how many patients are stopping treatment, and does what's being seen in actual practice line up with the results from the clinical trials? And then regarding sickle cell, I believe you've taken us through the kinds of data you'll be reviewing, but I'd like to know whether there are any particular deal breakers tied to the factor under examination that would trigger a no-go choice. If you wouldn't mind laying out that scenario for us. Thanks very much.

Brian Goff

executive
#48

Certainly; we'll handle that in order once more. Sveta is welcome to begin with the PKD discontinuations, after which Sarah will take sickle cell.

Tsveta Milanova

executive
#49

Sure. Like we said before, it's genuinely encouraging that the effectiveness of PYRUKYND that we saw in the clinical trials and the experience there is carrying over quite strongly into patients staying on treatment in the real-world setting. Keeping that in mind, discontinuations have stayed lower on the whole, and up to now. As we noted, reauthorizations haven't become an obstacle, and adherence to the product is still strong. I think this really reflects the PYRUKYND value proposition in PKD, but it also gives us encouragement that the significance of persistency tied to PYRUKYND might potentially carry over into other indications, future indications we're aiming to expand into. That could be a key differentiator, given how much persistency and adherence matter in other diseases.

Brian Goff

executive
#50

Great. Sarah?

Sarah Gheuens

executive
#51

Yes, so regarding that aspect of the clinical study, the persistence and adherence observed in our trials have enabled us to keep tracking patients through the long-term extensions, which in turn has let us keep examining maintenance of effect, along with how patients feel and function. We're also quite enthusiastic about the iron overload findings we keep sharing. As Sveta noted, that compelling data across the board matters greatly to us, since we also evaluate it within the broader context of other hemolytic anemias. Now moving to another hemolytic anemia, sickle cell disease. When it comes to the no-go scenarios, certain ones are obvious, such as what would occur in the clinical trial, as one would expect for a clinical trial, namely when a clinical trial fails. For example, if no hemoglobin response appears in the primary endpoint, or a safety signal shifts the benefit-risk profile in the wrong direction, such things are all proactively established within our go, no-go scenarios; just as with any other clinical development program, we have clear objectives followed by situations where additional data will need evaluation.

Anu Midha

analyst
#52

Thank you.

Brian Goff

executive
#53

Thank you.

Brian Goff

executive
#54

Much appreciated, and thank you all for joining the call today and, naturally, for the ongoing attention you show toward Agios. As was shared earlier today, we're achieving strong momentum throughout our portfolio. I feel tremendous pride in what the team is accomplishing for the patients who depend on us, and I have confidence in our ability to keep generating meaningful value for patients as well as for our shareholders. Many thanks, and we hope to talk with you again before long.

Operator

operator
#55

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.